Literature DB >> 35067760

Proteinopathies associated to repeat expansion disorders.

Anthony Fourier1,2, Isabelle Quadrio3,4.   

Abstract

The most common neurodegenerative disorders, such as Alzheimer's or Parkinson's diseases, are characterized by synaptic dysfunction, neuronal loss and proteinaceous aggregates in central nervous system. The deposition of misfolded proteins constitutes neuropathological hallmarks of these diseases, grouped in the generic term of proteinopathies. Apart from these, other neurodegenerative diseases are characterized by genetic abnormalities like unstable repetitive simple sequence tracts (microsatellites) dispersed throughout the human genome. They are called repeat expansion disorders and include, for example, Huntington's disease or frontotemporal dementia/amyotrophic lateral sclerosis phenotypes associated to an expansion in C9ORF72. The presence of the expanded DNA tract leads to molecular alterations at the DNA, RNA and protein levels associated to distinct mechanisms, such as loss-of-function (LOF), gain-of-function (GOF) including misfolding of physiological or mutant proteins, favoring their polymerization and aggregation. Therefore, specific proteinopathies also arise from these repeat expansion disorders. The molecular description of the nature and location of expanded tracts, highlighting the consequences onto clinical phenotypes will be first described. Specific focuses on the three pathomechanisms of the repeat expansions associated to proteinopathies will then be addressed. Lastly, we will show how progress in the understanding of these different mechanisms has led to recent advances in new/innovative therapeutic approaches and emergence of associated biomarkers.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Disease-modifying therapies; Neurodegenerative disorders; Polyglutamine diseases; Proteinopathies; RAN translation; Repeat expansions diseases

Mesh:

Substances:

Year:  2022        PMID: 35067760     DOI: 10.1007/s00702-021-02454-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  94 in total

Review 1.  Minisatellite instability and germline mutation.

Authors:  P Bois; A J Jeffreys
Journal:  Cell Mol Life Sci       Date:  1999-09       Impact factor: 9.261

Review 2.  RNAi therapeutics for CNS disorders.

Authors:  Ryan L Boudreau; Beverly L Davidson
Journal:  Brain Res       Date:  2010-03-20       Impact factor: 3.252

Review 3.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

4.  Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.

Authors:  N Ahmad Aziz; Martine J van Belzen; Ilona D Coops; René D M Belfroid; Raymund A C Roos
Journal:  Eur J Med Genet       Date:  2011-04-23       Impact factor: 2.708

5.  RAN Translation in Huntington Disease.

Authors:  Monica Bañez-Coronel; Fatma Ayhan; Alex D Tarabochia; Tao Zu; Barbara A Perez; Solaleh Khoramian Tusi; Olga Pletnikova; David R Borchelt; Christopher A Ross; Russell L Margolis; Anthony T Yachnis; Juan C Troncoso; Laura P W Ranum
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

Review 6.  Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

Authors:  Thomas A Bayer
Journal:  Eur Neuropsychopharmacol       Date:  2013-05-01       Impact factor: 4.600

7.  p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.

Authors:  Safa Al-Sarraj; Andrew King; Claire Troakes; Bradley Smith; Satomi Maekawa; Istvan Bodi; Boris Rogelj; Ammar Al-Chalabi; Tibor Hortobágyi; Christopher E Shaw
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

8.  Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Authors:  Lauren M Byrne; Filipe B Rodrigues; Kaj Blennow; Alexandra Durr; Blair R Leavitt; Raymund A C Roos; Rachael I Scahill; Sarah J Tabrizi; Henrik Zetterberg; Douglas Langbehn; Edward J Wild
Journal:  Lancet Neurol       Date:  2017-06-07       Impact factor: 44.182

Review 9.  Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications.

Authors:  Ana Maria Cabal-Herrera; Nattaporn Tassanakijpanich; Maria Jimena Salcedo-Arellano; Randi J Hagerman
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

10.  An RNA hairpin to G-quadruplex conformational transition.

Authors:  Anthony Bugaut; Pierre Murat; Shankar Balasubramanian
Journal:  J Am Chem Soc       Date:  2012-11-29       Impact factor: 15.419

View more
  2 in total

Review 1.  Valosin Containing Protein (VCP): A Multistep Regulator of Autophagy.

Authors:  Veronica Ferrari; Riccardo Cristofani; Barbara Tedesco; Valeria Crippa; Marta Chierichetti; Elena Casarotto; Marta Cozzi; Francesco Mina; Margherita Piccolella; Mariarita Galbiati; Paola Rusmini; Angelo Poletti
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

Review 2.  Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets.

Authors:  Kazumoto Shibuya; Ryo Otani; Yo-Ichi Suzuki; Satoshi Kuwabara; Matthew C Kiernan
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.